CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
申请人:Millennium Pharmaceuticals, Inc.
公开号:US20160031908A1
公开(公告)日:2016-02-04
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by:
or physiologically acceptable salt thereof.
Chemokine receptor antagonists and methods of use thereof
申请人:Luly R. Jay
公开号:US20050070549A1
公开(公告)日:2005-03-31
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.
Process for the preparation of halophthalic anhydrides
申请人:Occidental Chemical Corporation
公开号:US05049682A1
公开(公告)日:1991-09-17
Halophthalic anhydrides are prepared by the liquid phase reaction of a brominating agent with halogen substituted hexa- or tetra-hydrophthalic anhydrides.
卤代己酸酐通过液相反应与卤代的六氢苯并二酐或四氢苯并二酐制备。
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
申请人:Luly Jay R.
公开号:US20090281081A1
公开(公告)日:2009-11-12
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by:
or physiologically acceptable salt thereof.
Chemokine receptor antagonists and methods of use therefor
申请人:Luly R. Jay
公开号:US20070060592A1
公开(公告)日:2007-03-15
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by:
or physiologically acceptable salt thereof.